

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

北斗嘉藥業股份有限公司
BAYTACARE PHARMACEUTICAL CO., LTD.*

(a joint stock limited company incorporated in the People's Republic of China)

(Stock Code: 8197)

PROPOSED APPOINTMENT OF DIRECTORS

The board (the “**Board**”) of directors (the “**Directors**”) of Baytacare Pharmaceutical Co., Ltd.* (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the following individuals have been nominated as candidates for their respective roles set out below for election at the forthcoming annual general meeting of the Company to be held on 30 June 2019 (the “**AGM**”) subject to the approval by the shareholders of the Company (the “**Shareholders**”).

1. Ms. Zheng Chunyan (鄭春燕女士) has been nominated as a candidate for election at the AGM as an executive Director;
2. Ms. Zhao Xiaomei (趙曉梅女士) has been nominated as a candidate for election at the AGM as an independent non-executive Director; and
3. Mr. Zhu Tianxiang (朱天相先生) has been nominated as a candidate for election at the AGM as an independent non-executive Director.

Set out below are the biographies of:

Ms. Zheng Chunyan (鄭春燕女士)

Ms. Zheng Chunyan, aged 35, graduated from Southwest China Normal University with an undergraduate degree in English in 2005. From June 2005 to January 2006, Ms. Zheng served as a translator and the assistant to the General Manager in Loncin Group. From March 2006 to May 2009, she served as the secretary to the Chairman and translator of Sing Heng Chan (Chongqing) Construction Materials Co., Ltd.* (新興棧(重慶)建材有限公司) (a company of a Singapore Listed Group). From May 2009 to August 2012, she served as Executive Vice President and assistant to the Chairman of Dixi Trading Co., Ltd.* (帝西商貿有限公司), a wholly-owned subsidiary of Sing Heng Chan (Chongqing) Construction Materials Co., Ltd. From October 2012 to January 2014, she served as Operation Manager and assistant to the Chairman of Chongqing Leilong Trading Co., Ltd. (Harley-Davidson Chongqing)* (重慶雷隆商貿有限公司(哈雷戴維森重慶)). Ms. Zheng has served as the assistant to the Chairman of Chongqing Siya Pharmaceutical Co., Ltd.* (重慶思亞醫藥有限公司) and the Deputy General Manager of its subsidiary since July 2015.

Save as disclosed above, Ms. Zheng does not hold any directorships in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years, any other positions with the Company and other members of the Group, or any major appointments and professional qualifications.

Ms. Zheng does not have any relationship with any Directors, senior management, substantial or controlling shareholders of the Company and she has no interests in the shares of the Company which are required to be disclosed pursuant to Part XV of the SFO.

Save as disclosed herein, there are no other matters relating to the appointment of Ms. Zheng that need to be brought to the attention of the shareholders and there is no information which is required to be disclosed pursuant to Rule 17.50(2)(h) to (v) of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited.

Ms. Zheng will enter into a director's service contract with the Company for a term of service of three years commencing from the date of the AGM, subject to rotation and re-election at the annual general meeting of the Company in accordance with the articles of association of the Company. Ms. Zheng's remuneration will be determined by the Board with reference to her duties, responsibilities as well as the Company's remuneration policy and the market benchmark.

Ms. Zhao Xiaomei (趙曉梅女士)

Ms. Zhao Xiaomei, aged 45, graduated from Xinxiang Medical University in 1998. From April 2001 to October 2006, Ms. Zhao served as Deputy General Manager of the China Advertising Association Special Operations Company* (中國廣告協會專項運營公司) and Zhongguang Tuopu Advertising Media Co., Ltd.* (中廣托普廣告傳媒有限公司). From October 2006 to March 2012, she served as the Chief Planning Officer, Chief Marketing Officer and Chief Strategy Officer of Minsheng Pharmaceutical E-Commerce Company* (民生醫藥電子商務網公司). From March 2012 to December 2012, she served as the partner engaged in the outsourcing of marketing projects. From December 2012 to September 2013, she served as the Director of E-Commerce of Gansu Longxi Zhongtian Pharmaceutical Co., Ltd.* (甘肅隴西中天藥業公司) (currently known as Tasly Zhongtian Pharmaceutical Co., Ltd.* (天士力中天藥業公司)). From January 2014 to December 2016, she served as the Deputy General Manager of Chongqing Pharmaceutical Public Credit Co., Ltd.* (重慶醫藥公信網有限公司), a wholly-owned subsidiary of Chongqing Medicine Exchange and the Director of Pharmaceutical Public Credit Pharmacy Chain Co., Ltd. and Wholesale Co., Ltd.* (醫藥公信網大藥房連鎖有限公司 and 批發有限公司), both being the holding subsidiaries of Chongqing Medicine Exchange. Ms. Zhao has served as Deputy Minister of Strategic Development Department and Deputy Director of Transaction Research Center at Chongqing Medicine Exchange Co., Ltd. since January 2017.

Save as disclosed above, Ms. Zhao does not hold any directorships in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years, any other positions with the Company and other members of the Group, or any major appointments and professional qualifications.

Ms. Zhao does not have any relationship with any Directors, senior management, substantial or controlling shareholders of the Company and she has no interests in the shares of the Company which are required to be disclosed pursuant to Part XV of the SFO.

Save as disclosed herein, there are no other matters relating to the appointment of Ms. Zhao that need to be brought to the attention of the shareholders and there is no information which is required to be disclosed pursuant to Rule 17.50(2)(h) to (v) of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited.

Ms. Zhao will enter into a director's service contract with the Company for a term of service of three years commencing from the date of the AGM, subject to rotation and re-election at the annual general meeting of the Company in accordance with the articles of association of the Company. Ms. Zhao's remuneration will be determined by the Board with reference to her duties, responsibilities as well as the Company's remuneration policy and the market benchmark.

Mr. Zhu Tianxiang (朱天相先生)

Mr. Zhu Tianxiang, aged 46, graduated from the School of Accountancy of Jiangxi College of Finance and Economics with a degree in international accounting and securities investment. Mr. Zhu has extensive experience in financial management and possesses professional qualification in accounting. He served as a manager of financial department in various companies from August 1994 to July 2002. From December 2004 to June 2008, Mr. Zhu served as a senior management member, a member of the president office, the chief duty compliance officer and the vice president of Founder Securities Limited. Subsequently, Mr. Zhu occupied various important positions in Credit Suisse Founder Securities Limited such as financial controller and secretary to the board. In addition, Mr. Zhu also served as the group general manager of Shenzhen Dasheng Agricultural Group Co., Ltd.* (深圳市大生農業集團有限公司). Mr. Zhu once served as a director and general manager of Shangdong Jiangquan Company Limited* (山東江泉股份有限公司) and a non-executive director of Shanghai Dasheng Agriculture Finance Technology Co., Ltd. (formerly known as Shanghai Tonva Petrochemical Co., Ltd.) (Hong Kong listed company stock code: 1103). Mr. Zhu is currently an executive director of Sino Energy International Holdings Group Limited (Hong Kong listed company stock code: 1096).

Save as disclosed above, Mr. Zhu does not hold any directorships in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years, any other positions with the Company and other members of the Group, or any major appointments and professional qualifications.

Mr. Zhu does not have any relationship with any Directors, senior management, substantial or controlling shareholders of the Company and he has no interests in the shares of the Company which are required to be disclosed pursuant to Part XV of the SFO.

Save as disclosed herein, there are no other matters relating to the appointment of Mr. Zhu that need to be brought to the attention of the shareholders and there is no information which is required to be disclosed pursuant to Rule 17.50(2)(h) to (v) of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited.

Mr. Zhu will enter into a director's service contract with the Company for a term of service of three years commencing from the date of the AGM, subject to rotation and re-election at the annual general meeting of the Company in accordance with the articles of association of the Company. Mr. Zhu's remuneration will be determined by the Board with reference to his duties, responsibilities as well as the Company's remuneration policy and the market benchmark.

A notice of AGM and a circular containing, among other matters, details of the proposed appointments, will be despatched to the Shareholders on 15 May 2019.

Trading in the shares of the Company has been suspended with effect from 9am on 27 September 2018, and will continue to be suspended until further notice.

By Order of the Board
Baytacare Pharmaceutical Co., Ltd.*
Executive Director
Cui Bingyan

Shenzhen, People's Republic of China, 14 May 2019

As at the date of this announcement, the executive Directors are Cui Bingyan, Fang Yao and Guo Aiqun; the non-executive Directors are Shi Peng and Cao Yang; and the independent non-executive Directors are Chen Youfang and Zhu Tianxiang.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Company Announcements" page of the website of GEM at www.hkgem.com for at least 7 days from the date of the publication and the Company's website at www.baytacare.com from the date of this announcement.

* for identification purposes only